anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Bleeding in the pelvis can lead to a circulatory problem. The widely used whole-body computed tomography (WBCT) scan in the context of treatment in the trauma resuscitation unit (TRU) can give an idea of the source of bleeding (arterial vs. venous/osseous); however, the volume determination of an intrapelvic hematoma by volumetric planimetry cannot be used for a quick estimation of the blood loss. Simplified measurement techniques using geometric models should be used to estimate the extent of bleeding complications.
OBJECTIVE: To determine whether simplified geometric models can be used to quickly and reliably determine intrapelvic hematoma volume in fractures type Tile B/C during emergency room diagnostics or whether the time-consuming planimetric method must always be used.
MATERIAL AND METHODS: Retrospectively, 42 intrapelvic hemorrhages after pelvic fractures Tile B + C (n = 8:B, 34:C) at two trauma centers in Germany were selected (66% men, 33% women; mean age 42 ± 20 years) and the CT scans obtained during the initial trauma scan were analyzed in more detail. The CT datasets of the included patients with 1-5 mm slice thickness were available for analysis. By area labelling (ROIs) of the hemorrhage areas in the individual slice images, the volume was calculated by CT volumetrically. Comparatively, volumes were calculated using simplified geometric figures (cuboid, ellipsoid, Kothari). A correction factor was determined by calculating the deviation of the volumes of the geometric models from the planimetrically determined hematoma size.
RESULTS AND DISCUSSION: The median planimetric bleeding volume in the total collective was 1710 ml (10-7152 ml). Relevant pelvic bleeding with a total volume > 100 ml existed in 25 patients. In 42.86% the volume was overestimated in the cuboid model and in 13 cases (30.95%) there was a significant underestimation to the planimetrically measured volume. Thus, we excluded this volume model. In the models ellipsoid and measuring method according to Kothari, an approximation to the planimetrically determined volume could be achieved with a correction factor calculated via a multiple linear regression analysis. The time-saving and approximate quantification of the hematoma volume using a modified ellipsoidal calculation according to Kothari makes it possible to assess the extent of bleeding in the pelvis after trauma if there are signs of a C-problem. This measurement method, as a simple reproducible metric, could be embedded in trauma resuscitation units (TRU) in the future.
In lithotomy position, . Under fluoroscopic guidance, the desired calyces will be punctured using an 18 G coaxial needle. Then 0.038 mm hydrophilic guidewires will be passed percutaneously through the needle into the pelvis. Using metal dilators dilatation will be carried out. Amplatz sheath will be inserted to allow nephroscope to enter the collecting system. Stone disintegration will be performed using pneumatic, ultrasonic or laser lithotripsy. Eventually after removal of all stone fragments, a nephrostomy tube will be placed.
This invention relates to a cap pad structure of IC lead frame. The IC lead frame is mainly provided with the cap pad and a plurality of connecting feet positioned around the circumference of the cap pad. The cap pad is composed of a center recessed portion for placing a chip of an IC thereon and a frame portion surrounding the center portion, nearly shaped as an inverted hat. In packaging an IC, this cap pad can prevent the glue of the chip from overflowing out of the center recessed portion and worsening the function of leads. And in filling epoxy resin in the IC, the epoxy resin should be blocked from overflowing out of the cap pad and affecting the effect of heat dispersion of the IC. If temperature changes in packaging, a right angled lower circumference of the cap pad enables it immersed in the epoxy resin so that the cap pad will improve the delimitation in between cap pad and epoxy resin, stepping up the productivity of IC packaging and its quality.
A total of 29 eligible subjects will be enrolled to receive high titer anti-SARS-CoV-2 plasma. Participants will be compared to a historical control group via retrospective chart review.
The present invention relates to composition of nanometer SOD and kudzuvine root or the extract of kudzuvine root, and a preparation method of the composition. In 1 to 100000 active units of nanometer SOD, 1 to 50 g of nanometer kudzuvine root or the extract of kudzuvine root is contained, and the grain size is smaller than or equal to 10 to 80 nanometers. Nanometer operation is carried out to the composition of SOD and kudzuvine root or the extract of kudzuvine root, or the combination comprises nanometer SOD and nanometer kudzuvine root or the extract of nanometer kudzuvine root. The combination application of the nanometer composition of the nanometer SOD and the kudzuvine root or the extract of kudzuvine root enhances the concentration and the effective components of the drug. The anti-oxidation activity is enhanced by more than 10 times, the skin and mucous membrane absorption rate reaches more than 98%, and the half life is prolonged by more than two orders of magnitude. The composition of nanometer SOD and kudzuvine root or the extract of kudzuvine root can enter cells to directly clear free radicals, and has stronger anti-lipid peroxidation. The comprehensive drug effect is more thoroughly exerted and is much better than the drug effect of the traditional compound Chinese drugs. The composition of nanometer SOD and kudzuvine root or the extract of kudzuvine root is used for enhancing the anti-anoxia capability, exerting anti-fatigue efficiency, and enhancing exercise tolerance, and is suitable for athletes, emergent patients, and people with external wounds. The absorption speed is very high. The drug effect is 3 to 5 times higher than that of SOD and is 5 to 10 times higher than that of milkvetch root. The composition of nanometer SOD and kudzuvine root or the extract of kudzuvine root is contribution to the human medicine career.
The premarketing development program for citalopram included citalopram exposures in patients and/or normal subjects from 3 different groups of studies: 429 normal subjects in clinical pharmacology/pharmacokinetic studies; 4422 exposures from patients in controlled and uncontrolled clinical trials, corresponding to approximately 1370 patient-exposure years. There were, in addition, over 19,000 exposures from mostly open-label, European postmarketing studies. The conditions and duration of treatment with citalopram varied greatly and included (in overlapping categories) open-label and double-blind studies, inpatient and outpatient studies, fixed-dose and dose-titration studies, and short-term and long-term exposure. Adverse reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, ECGs, and results of ophthalmologic examinations.  
  
Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, standard World Health Organization (WHO) terminology has been used to classify reported adverse events.  
  
The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.
OTf + FeSO4 - This is the experimental arm where Ferrous sulfate will be given to the participants along with apo-Ovotransferrin, a potential iron absorption enhancer. They will be given as solutions that will be spread on bread with butter and honey, a breakfast meal.
Pulmonary fibrosis is a chronic and progressive disease, current systemic administration is not fully effective with many side effects, such as gastrointestinal and liver injury. The pulmonary delivery system for pulmonary fibrosis may contribute to maximize therapeutic benefit. Natural compounds might have prominence as potential drug candidates, but the low bioavailabilities affect their clinical use. Tetrandrine is a natural alkaloid with good anti-inflammatory, antifibrogenetic and antioxidant effects, and it is used as a clinical therapeutic drug for the treatment of silicosis in China. In the present study, we explore a new strategy of pulmonary delivery system to improve low solubility and pesticide effect of tetrandrine. Tetrandrine was loaded into alginate nanogels by reverse microemulsion method. The release behavior of tetrandrine reached zero-order kinetics release and the maximum free radical clearance rates reached up to 90%. The pulmonary fibrosis rats were treated with tetrandrine nanogels by using ultrasonic atomizing inhalation. Tetrandrine nanogels decreased the development and progression of fibrosis by reducing inflammation response and bating the deposition of extra cellular matrix. In conclusion, ultrasonic atomizing inhalation of tetrandrine nanogels provided a new therapeutic strategy for pulmonary fibrosis.
The invention discloses application of a targeted complement inhibitor in preparation of a medicine for improving liver aging. The application of a targeted complement inhibitor CR2-Crry in preparing a medicine for improving liver aging is disclosed, wherein the amino acid sequence of CR2-Crry is shown as SEQ ID NO. 1. The targeted complement inhibitor CR2-Crry can improve the aging index of a D-galactose-induced liver aging model. The mice are injected with 800mg/kg of D-galactose every day subcutaneously for 8 weeks, and a mouse aging model is established. Mice in the experimental group were injected subcutaneously with D-galactose for 1 week, and were initially intraperitoneally administered with CR2-crry protein 0.08mg daily. After 8 weeks, liver tissues and serum were taken and the aging changes of the liver were examined by aging index.
Catatonia is a complex syndrome with unique cognitive, psychomotor, and mood features. Mannerisms and stereotypies are catatonic signs that have been extensively observed and described in the literature, mostly in the context of movements or motor acts. Stereotypies are commonly described as repetitive psychomotor or verbal acts with the abnormality not inherent in the act but in its frequency. Mannerisms, like stereotypies, are repetitive psychomotor or verbal acts, but they are fundamentally odd in nature. Recently, several reports have described these phenomena in the context of complex behaviors, such as eating and drinking. Identification and appreciation of personal and cultural norms, in addition to a careful analysis of behavioral processes and actions, are important tools for clinicians to identify these potentially elusive and often missed patterns of behavior in patients with catatonia. We present the case of a 30-year-old male with a psychiatric history of treatment-resistant, recurrent major depressive disorder with psychotic features who presented to the inpatient psychiatric unit with signs of catatonia, including repeated, purposeless eating. The patient's chart was reviewed, and a literature review was conducted using PubMed with the keywords catatonia, stereotypies, mannerisms, and hyperphagia. The patient, who was diagnosed with catatonia and expressed hyperphagia as a stereotypy, responded to lorazepam. This case shows that hyperphagia may present as a stereotypy in patients with catatonia.
von Willebrand factor (VWF) is an essential contributor to microvascular thrombosis. Physiological cleavage by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) limits its prothrombotic properties, explaining why ADAMTS13 deficiency leads to attacks of microthrombosis in patients with thrombotic thrombocytopenic purpura (TTP). We previously reported that plasminogen activation takes place during TTP attacks in these patients. Furthermore, stimulation of plasminogen activation attenuates pathogenesis in preclinical TTP models in vivo. This suggests that plasmin is an endogenous regulator of VWF thrombogenicity, in particular when ADAMTS13 falls short to prevent microvascular occlusions. VWF cleavage by plasmin is biochemically distinct from cleavage by ADAMTS13. We hypothesized that plasmin-cleaved VWF (cVWF) holds value as a biomarker of microvascular thrombosis. Here, we describe the development of a variable domain of heavy-chain-only antibody (VHH)-based bioassay that can distinguish cVWF from intact and ADAMTS13-cleaved VWF in plasma. We validate this assay by tracking cVWF release during degradation of microthombi in vitro. We demonstrate that endogenous cVWF formation takes place in patients with TTP during acute attacks of thrombotic microangiopathy but not in those in remission. Finally, we show that therapeutic plasminogen activation in a mouse model of TTP amplifies cVWF formation, which is accompanied by VWF clearance. Our combined findings indicate that cVWF is released from microthrombi in the context of microvascular occlusion.
Participants received 5-Fluorouracil (5-FU) 800 mg/m\^2 per 24 hours as continuous IV infusion over 120 hours from Day 1 through Day 5 followed by a 16-day rest period on Days 6 through 21 in a 21-day cycle. Participants received a single dose of cisplatin 80 mg/m\^2 as a 1- to 3-hour IV infusion on Day 1 prior to the start of the 5-FU infusion on Day 1 for a maximum of 8 cycles (each cycle of 21 days). Participants received study medication until PD, AE, withdrawal of consent, or other reason for discontinuation, whichever happened earlier.
Previous studies have reported that bodily self-consciousness could be altered so that one's body was perceived in extra-personal space. However, whether this could be induced without tactile stimuli has not been investigated. We investigated whether out-of-body illusion could be induced via synchronized audio-visual stimuli, in which auditory stimuli were used instead of tactile stimuli. We conducted an experiment in which a sounding bell was moved in front of the participant, and synchronously, a non-sounding bell was moved in front of a camera that captured the image and projected on a head-mounted device. We expected the participants to experience that the sound came from the non-sounding bell in the video and they were in the camera's position. Results from the questionnaires conducted after the experiment revealed that items related to out-of-body illusion were significantly enhanced in the synchronized conditions. Furthermore, participants reported a similarly strong out-of-body illusion for both the synchronized audio-visual and tactile-visual stimuli. This study demonstrated that out-of-body illusion could also be induced by synchronized audio-visual stimuli, which was a novel finding.
Patients receive CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment may repeat for an additional cycle for a total of 2 cycles (on days 1 and 3 only of cycle 2) in the absence of disease progression or unacceptable toxicity. Within 60 days after completion of CPX-351, patients undergo alloHCT.
<P>PROBLEM TO BE SOLVED: To obtain a human body harmful substance-removing agent which is characterized by using Brassica oleracea acephala and removes chlorine-containing chlorine-based harmful substances such as dioxins, PCB and chlorine-containing agricultural chemicals.  <P>SOLUTION: This human body harmful substance-removing agent is characterized by containing Brassica oleracea acephala of cruciferous plant as an active ingredient. The Brassica oleracea acephala itself, its processed product such as crushed product, milled product, pasty product, or juice, and/or treated product such as the frozen product or dry powder of the Brassica oleracea acephala processed product is used as the Brassica oleracea acephala. For example, a Brassica oleracea acephala product (green soup) obtained by screw-pressing cut Brassica oleracea acephala to remove coarse fibers can advantageously be used. Only by orally administering the Brassica oleracea acephala, harmful substances such as dioxins, PCB, organic chlorine-based agricultural chemicals (DDT, BHC), and others can be removed from human bodies.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Congenital diarrheas and enteropathies (CODE) are a group of rare, heterogenous, monogenic disorders that lead to chronic diarrhea in infancy. Definitive treatment is rarely available, and supportive treatment is the mainstay. Nutritional management in the form of either specialized formulas, restrictive diet, or parenteral nutrition support in CODE with poor enteral tolerance is the cornerstone of CODE treatment and long-term growth. The evidence to support the use of specific diet regimens and nutritional approaches in most CODE disorders is limited due to the rarity of these diseases and the scant published clinical experience. The goal of this review was to create a comprehensive guide for nutritional management in CODE, based on the currently available literature, disease mechanism, and the PediCODE group experience. Enteral diet management in CODE can be divided into 3 distinct conceptual frameworks: nutrient elimination, nutrient supplementation, and generalized nutrient restriction. Response to nutrient elimination or supplementation can lead to resolution or significant improvement in the chronic diarrhea of CODE and resumption of normal growth. This pattern can be seen in CODE due to carbohydrate malabsorption, defects in fat absorption, and occasionally in electrolyte transport defects. In contrast, general diet restriction is mainly supportive. However, occasionally it allows parenteral nutrition weaning or reduction over time, mainly in enteroendocrine defects and rarely in epithelial trafficking and polarity defects. Further research is required to better elucidate the role of diet in the treatment of CODE and the appropriate diet management for each disease.
The invention relates to the technical field of Chinese herbal cold-treating medicines and relates to compound Neelubar cold-treating granules and a production method thereof. The raw materials contain, by weight, 5-15 parts of Artemisia rupestris L, 3-9 parts of Hyssopus officinalis, 5-15 parts of dried ginger, 3-9 parts of trollius chinensis bunge, 5-15 parts of Po bu mu go, 3-9 parts of jujube and 3-9 parts of licorice. The invention discloses compound Neelubar cold-treating granules for treating cold. The medicine has a good antiviral effect. In addition, the compound Neelubar cold-treating granules have a good effect of inhibiting influenza virus M2 protein and mRNA level in MDCK cells. Therefore, the medicine has little toxic and side effect relative to western medicines. Meanwhile, the problem that a traditional Chinese herbal decoction has a great impact on clinical efficacy and is inconvenient to carry when medication dosage is high is effectively solved.
Cardiovascular diseases (CVDs) encompass various conditions affecting the heart and its blood vessels and are often linked with oral microbes. Our data analysis aimed to identify oral bacteria from other non-oral sites (i.e., gut, arterial plaque and cultured blood) that could be linked with CVDs. Taxonomic profiling identified bacteria to the species level and compared with the Human Oral Microbiome Database (HOMD). The oral bacteria in the gut, cultured blood and arterial plaque samples were catalogued, with their average frequency calculated for each sample. Additionally, data were filtered by comparison with the Human Microbiome Project (HMP) database. We identified 17,243 microbial species, of which 410 were present in the HOMD database and further denominated as "oral", and were found in at least one gut sample, but only 221 and 169 species were identified in the cultured blood and plaque samples, respectively. Of the 410 species, 153 were present solely in oral-associated environments after comparison with the HMP database, irrespective of their presence in other body sites. Our results suggest a potential connection between the presence of specific species of oral bacterial and occurrence of CVDs. Detecting these oral bacterial species in non-oral sites of patients with CVDs could help uncover the link between oral health and general health, including cardiovascular conditions via bacterial translocation.
<P>PROBLEM TO BE SOLVED: To provide a new vector, and a DNA vaccine and a gene therapeutic containing the vector, to provide methods for producing the vector, and the DNA vaccine and the gene therapeutic containing the vector, and to provide a method for therapeutically using the vector.  <P>SOLUTION: The vector comprises (a) an expression cassette of a gene of a nuclear-anchoring protein, which contains (i) a DNA binding domain bindable to a specific DNA sequence and (ii) a functional domain bindable to a nuclear component, (b) a multimerized DNA forming a binding site for the nuclear-anchoring protein, and (c) one or more expression cassettes of a DNA sequence of interest. In particular, the vector lacks a papilloma virus origin of replication and a functional replication origin in a mammal cell. The nuclear-anchoring protein includes the E2 protein of bovine papilloma virus type 1 or E2 protein of Epstein-Barr virus nuclear antigen 1. The method for expressing a DNA sequence of interest in a subject is also provided.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention relates to a Parkinson health risk assessment method based on multi-modal data, which comprises the steps of preparing UPDRS scoring, population basic condition data and sensor data, and constructing a multi-modal data set; preprocessing the sensor data by Gaussian filtering; and (3) building a convolutional neural network model and constructing a sensor data feature extraction method based on deep learning. And the manual characteristics are integrated, and the sensor data are calculated to be characteristics which have important significance for the assessment of the Parkinson health risk. And integrating the demographic data and fusing the demographic data into the model. Model training and prediction, and integrating the features extracted by the convolutional neural network, manual features and demographic data features. And constructing a feature representation consistency module based on the three types of features. Finally, the model is trained and samples of unknown labels are predicted. The accuracy of the method and the model in the Parkinson risk prediction reaches 81.4%.